Trials / Completed
CompletedNCT05407220
A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of HCP1904 in Healthy Male Volunteers.
A Randomized, Open-Label, Single-Dose Parallel Study to Evaluate the Pharmacokinetics, Safety and Tolerability of HCP1904 in Healthy Male Volunteers.
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 16 (actual)
- Sponsor
- Hanmi Pharmaceutical Company Limited · Industry
- Sex
- Male
- Age
- 19 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
A Randomized, Open-Label, Single-Dose Parallel Study to Evaluate the Pharmacokinetics, Safety and Tolerability of HCP1904 in Healthy Male Volunteers.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HCP1904-1 | take it once per period |
| DRUG | HCP1904-3 | take it once per period |
Timeline
- Start date
- 2022-06-29
- Primary completion
- 2022-07-25
- Completion
- 2022-07-25
- First posted
- 2022-06-07
- Last updated
- 2024-10-08
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT05407220. Inclusion in this directory is not an endorsement.